Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 15/20 | 0.36 |
| ▸ | BRAF | P15056 | 6/20 | 0.35 |
| ▸ | RAF1 | P04049 | 4/20 | 0.35 |
| ▸ | TEK | Q02763 | 4/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459695 | 0.90 | KDR (0.41) | PIM1KDRBRAFRAF1TEK | |
| SCHEMBL5444075 | 0.90 | KDR (0.41) | PIM1KDRBRAFRAF1TEK | |
| SCHEMBL5447363 | 0.81 | CSNK1D (0.35) | KDRBRAFRAF1TEKCSNK1D | |
| SCHEMBL5448427 | 0.81 | KDR (0.41) | PIM1KDRBRAFRAF1TEK | |
| SCHEMBL5459650 | 0.77 | RAF1 (0.43) | KDRBRAFRAF1TEKCSNK1A1 | |
| SCHEMBL5452397 | 0.75 | PIM1 (0.31) | PIM1KDR | |
| SCHEMBL5458915 | 0.74 | KDR (0.35) | KDRBRAFRAF1TEK | |
| SCHEMBL5447181 | 0.74 | RAF1 (0.44) | KDRBRAFRAF1TEKCSNK1A1 | |
| SCHEMBL11017298 | 0.73 | L3MBTL1 (0.40) | KDRBRAF | |
| SCHEMBL5444136 | 0.72 | RIPK1 (0.40) | PIM1KDRBRAFRAF1TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021456-A1 | Aminobenzimidazole derivatives | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | claimed |
| US-20070021456-A1 | Aminobenzimidazole derivatives | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021456-A1 | Aminobenzimidazole derivatives | TIE1, KDR, FLT1 | PIM1 249/4885KDR 2/4885BRAF 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.